If this message does not display properly, please click here to launch your browser.
|
Based on our Pharmacor advisory service entitled Psoriasis, Decision Resources is offering an exclusive analyst call entitled In Light of Safety Concerns, Abbott’s Briakinumab Faces a Rough Road Ahead in the Psoriasis Drug Market. Because this presentation will feature major updates, it is ONLY available to purchasers of this Pharmacor advisory service. Please contact us to learn how you can purchase this Pharmacor advisory service and attend the analyst call. Among the therapies poised to enter the psoriasis drug market in the next few years, Abbott’s briakinumab has the potential to have the greatest impact. If approved, briakinumab would join Centocor Ortho Biotech/Janssen Cilag’s Stelara as a second-in-class interleukin (IL) 12/23 inhibitor and would represent another treatment option for patients with moderate-to-severe psoriasis. Although both Stelara and briakinumab have shown superb efficacy and, as a result, threaten the dominance of the tumor necrosis factor-alpha (TNF-alpha) inhibitors, they suffer from a dearth of long-term safety data and a lack of approval in other indications. The results of three Phase III clinical trials—a 1,465-patient placebo-controlled study, and two head-to-head trials of briakinumab against etanercept (Amgen/Stiefel/Pfizer/Takeda’s Enbrel)—were reported in detail at the recent American Academy of Dermatology conference and the Third International Congress on Psoriasis. Based on the safety events which emerged from briakinumab’s placebo-controlled Phase III trial, Decision Resources forecasts that briakinumab will fall out of competition for first-line biologic status and be used mainly as later-line therapy in patients refractory to TNF-alpha inhibitors and Stelara. This 15-minute analyst call, presented by Analyst Iva Holder, Ph.D., will answer the following questions:
Dr. Holder will conduct a live Q & A session after the presentation. Registration In Light of Safety Concerns, Abbott’s Briakinumab Faces a Rough Road Ahead in the Psoriasis Drug Market September 7, 2010 at 10 a.m. U.S. Eastern Time, 4 p.m. Central European Time (Paris). To learn how you can purchase this Pharmacor advisory service and attend the analyst call, please contact us using the information below. In North America — Keith Rourke at 781-993-2656 or krourke@dresources.com |
|
||||
Terms of Use | Privacy Policy | Contact Us | Careers |
|||||
Iva Holder, Ph.D. is an analyst in the immune and inflammatory diseases group at Decision Resources. She received her B.A. from Smith College and her Ph.D. from Johns Hopkins University School of Medicine. Following postdoctoral research in the Department of Genetics at Harvard Medical School, she joined Decision Resources, where she is working on reports on irritable bowel syndrome and psoriasis.